Sofinnova Investments’s Cidara Therapeutics CDTX Stock Holding History

Sofinnova Investments’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-180,265	Closed	-$39.8M	–	78
2025 Q4	$39.8M	Buy	180,265 +126,068	+233%	+$20.4M	1.72%	18
2025 Q3	$5.19M	Sell	54,197 -196,834	-78%	-$12.6M	0.28%	52
2025 Q2	$12.2M	Buy	+251,031	New	+$6.03M	0.75%	36
2018 Q2	–	Sell	-648	Closed	-$52K	–	61
2018 Q1	$52K	Buy	+648	New	+$88.5K	0.01%	54

Sofinnova Investments's CDTX Position: Q1 2026 in Review

Sofinnova Investments sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 180,265 shares — an estimated $39.8M sold.

Sofinnova Investments first reported a position in CDTX in Q1 2018 and held it in 4 quarters. The position peaked at $39.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Sofinnova Investments reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Sofinnova Investments sold 180,265 Cidara Therapeutics shares in Q1 2026, an estimated $39.8M.
Sofinnova Investments first reported a position in Cidara Therapeutics in Q1 2018 and held it in 4 quarters.
Sofinnova Investments's Cidara Therapeutics position peaked at $39.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.